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Anatomic and Procedural Predictors
of Paravalvular Aortic Regurgitation After
Implantation of the Medtronic CoreValve Bioprosthesis
Mohammad A. Sherif, MD,* Mohamed Abdel-Wahab, MD,* Björn Stöcker, MD,* Volker Geist, MD,*
Doreen Richardt, MD,† Ralph Tölg, MD,* Gert Richardt, MD*
Bad Segeberg and Lübeck, Germany
Objectives The purpose of this study was to determine the predictors of aortic regurgitation (AR) after transcatheter aortic
valve implantation (TAVI).
Background TAVI has been associated with a high rate of paravalvular regurgitation, usually mild. Nevertheless, moderate to
severe regurgitations still occur and may have negative clinical consequences.
Methods Fifty patients with severe aortic stenosis were recruited and underwent successful TAVI with the Medtronic
CoreValve bioprosthesis through the transfemoral route. The end point of this study is the early occurrence of
significant AR, defined as the occurrence of grade II or more AR by post-procedural aortography.
Results The study population’s mean age was 80.5  7.9 years, with a mean aortic valve area of 0.64  0.17 cm2.
Post-procedural AR was absent in 3 patients and was grade I in 27 patients, grade II in 13 patients, and grade
III in 7 patients. Using univariate analysis, the chance of significant AR increased with increasing angle of left
ventricular outflow tract to ascending aorta (LVOT-AO) (odds ratio: 1.24, p  0.001). For the depth of the de-
vice in relation to the noncoronary cusp, there was a minimum chance of AR corresponding to depth  9.5 mm
(odds ratio: 1.1, p  0.01). Using multivariate analysis, we found a greater chance of significant AR with a
greater angle (odds ratio: 1.24, p  0.001), and that the chance of significant AR is a minimum when depth of
the device in relation to the noncoronary cusp is 10 mm (odds ratio: 1.1, p  0.024). A predictive model was
generated, and if 2 LVOT-AO  (depth to noncoronary cusp  10)2 50, the likelihood of occurrence of sig-
nificant AR could be predicted with a sensitivity of 85% and a specificity of 87%.
Conclusions The occurrence of significant AR after TAVI can be predicted by anatomic and procedural variables. A model
such as that presented can be used to select suitable patients for this procedure and guide operators during im-
plantation of the device. (J Am Coll Cardiol 2010;56:1623–9) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.035a
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trivial or mild paraprosthetic regurgitation is frequent after
urgical aortic valve replacement but does not have signifi-
ant impact on short- and long-term clinical outcomes (1).
owever, more severe paraprosthetic regurgitations might
ause hemodynamic deterioration or require reintervention
1). Similarly, paravalvular aortic regurgitation (AR) is
requent after transcatheter aortic valve implantation
TAVI) using the Medtronic CoreValve bioprosthesis
Medtronic, Minneapolis, Minnesota), but is usually mild
2). Importantly, moderate to severe regurgitations do occur
rom the *Heart and Vascular Center, Segeberger Kliniken GmbH, Academic
eaching Hospital of the University of Kiel, Bad Segeberg, Germany; and the
Cardiovascular Surgery Department, Schleswig-Holstein University Hospital, Lü-
eck, Germany. The authors have reported that they have no relationships to disclose.(
Manuscript received March 10, 2010; revised manuscript received June 11, 2010,
ccepted June 15, 2010.nd may have relevant clinical consequences; nevertheless,
he anatomic and procedure-related predictors of this com-
lication after implantation of the CoreValve bioprosthesis
ave not been specifically studied. Therefore, we sought to
hed light on these predictors and present a preliminary
redictive model for this complication.
ethods
tudy design. Fifty patients with severe symptomatic aortic
tenosis (aortic valve area [AVA] 1 cm2 or indexed AVA
0.6 cm2/m2) were recruited and underwent successful
AVI using the Medtronic CoreValve bioprosthesis
hrough the transfemoral route. Clinical and anatomic
election criteria and device size selection were in line with
he published investigational study for the third-generation
18-F) CoreValve device (2). Description of the device
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Predictors of AR After TAVI November 9, 2010:1623–9and technical aspects of the
procedure have been previously
published (2).
The end point of this study is
the early occurrence of significant
AR, defined as grade II or
greater AR, evaluated immedi-
ately after valve implantation us-
ing qualitative angiography with
visual estimation of the concen-
tration of contrast medium in the
left ventricle (3). The study pro-
tocol was approved by the ethics
committee of our institution. All
patients gave informed consent.
Echocardiographic assessment.
ransthoracic echocardiography was performed before and
mmediately after valve implantation. The severity of aortic
tenosis was assessed by the mean transvalvular gradient,
nd AVA calculated with the continuity equation (4). The
R was quantified using color-flow techniques that in-
luded measurement of the width and area of the AR jet at
he junction of the left ventricular outflow tract (LVOT)
nd the aortic annulus in the parasternal long-axis view in
elation to the maximum width and area of the LVOT at
he same location (5). The AR was graded as I for
rivial/mild, II for moderate, III for moderate to severe, and
V for severe (6,7). The aortic valve annulus diameter (mm)
as measured using transesophageal echocardiography
TEE) in the long-axis view. Aortic valve calcification relied
n visualization of bright echoes at the base of the aortic
alve leaflets using TEE, and was graded as mildly calcified
hen calcification appeared as small isolated spots, moder-
tely calcified when multiple larger spots were present, and
eavily calcified when extensive thickening and calcification
f all cusps was seen (8). The thickness of both the
oncoronary cusp (NCC) and the right coronary cusp was
easured in the long-axis view using TEE. Moreover,
istribution and localization (symmetric or asymmetric) of
alcification and number of cusps (tricuspid or bicuspid)
ere reported. Noteworthy, bicuspid aortic valves were
xcluded during screening of patients according to the
natomic boundaries that guide patient selection (9). The
nnulus was considered oval if the difference between the
nteroposterior diameter and the transverse diameter was
2 mm measured in short-axis view using TEE. Post-
peratively, the presence, degree, and type (paravalvular vs.
ransvalvular) of AR were recorded in all patients using
ransthoracic echocardiography.
ngiographic assessment. All patients underwent left
entriculography in 30° right anterior oblique (RAO) and
0° left anterior oblique projections and aortic root injection
n 50° left anterior oblique within 1 week before the
rocedure together with coronary angiography. The sinus of
alsalva diameter was measured as the largest width (mm)
Abbreviations
and Acronyms
AR  aortic regurgitation
AVA  aortic valve area
NCC  noncoronary cusp
RAO  right anterior
oblique
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiography
LVOT-AO  angle of left
ventricular outflow tract to
ascending aortaf the aortic root at the level of the aortic sinuses. The diameter of the ascending aorta was measured 45 mm above
he plane of the aortic annulus. Immediately after valve
eployment, aortography, to assess the degree of AR, in 30°
AO and 50° left anterior oblique projections was recorded
ver several cardiac cycles.
ngle of LVOT to ascending aorta measurement
LVOT-AO). We considered the angle between the axis
f the first 4 cm of the ascending aorta representing the
ontact surface with the upper part of the bioprosthesis and
he LVOT axis representing the landing zone of the
rosthesis. This angle was assessed using left ventriculogra-
hy in RAO 30° during preparation of the patients for the
rocedure. The LVOT-AO was measured using com-
ercially available software (JiveX Dicom Viewer, version
.0.2, VISUS Technology Transfer GmbH, Bochum, Ger-
any) as follows: the LVOT-axis was considered as a line
erpendicular to the plane of the LVOT; the aorta-axis is
he line passing in the first 4 cm and parallel to the aortic
all (Fig. 1).
valuation of device position. Depth of final device po-
ition in the LVOT was measured using a final aortogram of
he deployed bioprosthesis in RAO projection, displaying
he aortic valve in optimal alignment with all 3 leaflets
isible in the same plane. The depth of delivery was defined
s the distance from the native aortic annular margin on
he side of the NCC to the most proximal edge on the
orresponding side (deepest in the left ventricle) of the
Figure 1 Measurement of LVOT-AO Using
Left Ventriculography in RAO 30°
The LVOT-AO is the angle between the axis of the first 4 cm of the ascending
aorta (AO), representing the contact surface with the upper part of the biopros-
thesis, and the left ventricular outflow tract (LVOT) axis, representing the land-
ing zone of the prosthesis. This angle was assessed using left ventriculography
in right anterior oblique (RAO) projection 30° during preparation of the patients
for the procedure.eployed stent-frame (Fig. 2). In addition, the depth of
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November 9, 2010:1623–9 Predictors of AR After TAVIelivery from the annular margin of the left coronary cusp to
he corresponding side was measured (Fig. 2).
tatistical analysis. Statistical analysis was done using
initab software (Minitab, Release 13.1, State College,
ennsylvania). Data were expressed as mean  SD or
ercent. Comparisons of baseline and procedure-related
haracteristics of patients according to AR 2 or 2 were
erformed using the t test or chi-square test as appropriate.
ll potential predictors for the occurrence of significant AR
ere studied using univariate logistic regression analysis.
ome relationships were not completely linear, yet a curvi-
inear and a quadratic relationship could exist, so we have
lso checked whether a quadratic relationship with an
ntermediate optimum in each of the variables is present,
ut we have only reported details of the quadratic term
hen it was significant. Promising variables in the univar-
ate analysis (p  0.1) were included in a multivariate
ogistic regression with a backward selection approach, with
significant level of p  0.05. Adjusted odds ratio is
resented with 95% confidence interval. The logistic regres-
ion model was used to determine a preliminary prognostic
core for AR; the receiver-operating characteristic curve for
his score (i.e., a plot of sensitivity against 1-specificity for
ach cut-off value) was plotted, the area under the curve
Figure 2
Measurement of Depth of Medtronic CoreValve
Bioprosthesis Using Fluoroscopy in Relation
to NCC and LCC
The depth of the final device position in the left ventricular outflow tract mea-
sured using the final aortogram of the deployed bioprosthesis in the right ante-
rior oblique projection is shown. The depth of delivery is defined as the
distance from the native aortic annular margin on the side of both the noncoro-
nary cusp (NCC) and the left coronary cusp (LCC) to the most proximal edge on
the corresponding side of the deployed stent-frame. Figure was created by
Craig Skaggs.petermined, and a 95% confidence interval for the area
nder the curve found using the bootstrap method. The
orrelation between angiographic and echocardiographic
rading of AR was studied using Spearman rho correlation.
esults
aseline characteristics. Baseline clinical, echocardio-
raphic, angiographic, and procedural characteristics are
hown in Table 1. All 50 patients (age 80.5  7.9 years;
0% males) had severe aortic stenosis (mean AVA 0.64 
.17 cm2).
arly assessment of AR after TAVI. Angiographic grad-
ng of AR revealed absence of AR in 3 patients (6%), grade
in 27 patients (54%), grade II in 13 patients (26%), and
rade III in 7 patients (14%). Therefore, according to
ost-procedural angiography, 20 patients had significant
R (40%). Post-procedural transthoracic echocardiography
howed absence of paravalvular AR in 9 patients (18%),
rade I in 24 patients (48%), grade II in 13 patients (26%),
nd grade III in 4 patients (8%). No cases with grade IV or
ransvalvular AR were reported. The echocardiographic
rading of AR correlated well with the angiographic grading
r  0.8, p  0.001) (Fig. 3). The mean value of
LVOT-AO was significantly higher in patients with
ignificant AR compared with patients with no/mild AR
25.6  8.2° vs. 15.7  4.7°, respectively). The mean
istance from the ventricular end of the frame of the
rosthesis to the lower edge of both the NCC and the left
oronary cusp was comparable in both groups (Table 1).
redictors of significant AR. Univariate and multivariate
redictors of significant post-procedural AR are shown in
able 2. Using univariate analysis, we found a significant
vidence of an increased chance of significant AR with
ncreasing LVOT-AO (p  0.001). For the depth of the
evice in relation to the NCC, there was a quadratic
elationship, with the minimum chance of significant AR
orresponding to depth  9.5 mm. There was also a
uadratic relationship for the depth of the device in relation
o the left coronary cusp, with the minimum chance of
ignificant AR corresponding to depth  10.42 mm. The
ccurrence of significant AR was unrelated to septum
hickness, shape of annulus, ascending aorta diameter,
ulmonary hypertension, degree of leaflet calcification, pat-
ern of calcium distribution, annulus diameter, valve size,
nd baseline AR. Using multivariate analysis, we found a
reater chance of significant AR with greater angle, and that
he chance of significant AR is a minimum when depth of
he device in relation to NCC is10 mm, and tends to take
arger values when the depth is either smaller or larger.
redictive model for occurrence of significant AR. The
est suggested by the preceding analysis is as follows: test
ositive if 0.21314  LVOT-AO  1.8242  depth to
CC  0.091  (depth to NCC)2  k. The number k is
he cut-off point. To decide on a good value for k, we
lotted a receiver-operating characteristic curve and looked
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Predictors of AR After TAVI November 9, 2010:1623–9or values of k where the curve is close to the point (0, 1)
Fig. 4). This method suggested using k4.0459, so that
he test is positive if: 0.21314  LVOT-AO  1.8242 
epth  0.091  (depth to NCC)2 4.0459, with a
ensitivity of 90% and a specificity of 86.7%. However, this
est is rather complicated. We did simplify the model to the
ollowing: 2LVOT-AO (depth to NCC 10)2. An
ppropriate cut-off point is 50, so that the test is positive if
 LVOT-AO  (depth to NCC  10)2 50. With
his test, we obtained a sensitivity of 85% and a specificity of
6.7%. The cost of simplifying was to reduce the sensitivity
little. The relationship between the calculated score and
he degree of post-procedural AR in the whole cohort is
hown in Figure 5.
To address the contribution of the quadratic fit for depth
o NCC over LVOT-AO, we then looked at the sensi-
ivity and specificity of the test just based on the angle. This
esulted in a sensitivity of 85% and a specificity of 70%
aseline Clinical, Echocardiographic, Angiographic, and Procedural0 Pati nts Who Underwent Successful Implantation of the MedtroTable 1 Baseline Clinical, E ho ardiographic, A giographic, an50 Patients Who Underwent Successful Implantation o
Characteristics All (n  50)
Age, yrs 80.52 7.85
Height, cm 169.96 8.52
Weight, kg 76.66 15.09
BSA, m2 1.91 0.22
BMI, kg/m2 26.56 4.66
Echocardiographic parameters
Mean pressure gradient, mm Hg 50.38 17.22
AVA, cm2 0.64 0.17
iAVA, cm2/m2 0.34 0.09
Annulus, mm 23.26 1.41
Degree of leaflet calcification
Mild/moderate 27 (54.0%)
Severe 23 (46.0%)
Asymmetric calcification 28 (56.0%)
NCC thickness, mm 5.49 1.85
RCC thickness, mm 5.61 1.83
IVS thickness, mm 14.26 2.91
Baseline AR grade 0.88 0.69
Annulus shape, oval 19 (38.0%)
Ejection fraction, % 46.96 13.14
LVEDD, mm 52.36 10.40
Angiographic and procedural parameters
LVOT-AO 19.66 7.94
Sinus of Valsalva diameter, mm 29.74 3.37
Ascending aorta diameter, mm 30.04 4.47
Depth to NCC, mm 10.42 3.72
Depth to LCC, mm 11.35 3.72
Balloon diameter, mm 22.34 1.61
Valve size
29 mm 20 (40.0%)
26 mm 30 (60.0%)
Post-procedural AVA, cm2 1.89 0.15
Post-procedural iAVA, cm2/m2 1.00 0.14
alues are mean  SD or n (%).
AR aortic regurgitation; AVA aortic valve area; BMI body mass index; BSA body surface area; iA
eft ventricular end-diastolic diameter; LVOT-AO  angle between ascending aorta and left ventricular ocompared with 90% and 87%, respectively, when depth to
CC is included). Therefore, it seems that including depth
o NCC does improve the test to a worthwhile extent,
specially regarding its specificity.
iscussion
his study represents the first step toward a predictive model
or the occurrence of significant AR after implantation of the
edtronic CoreValve bioprosthesis. The results suggest that
he occurrence of significant AR is strongly related to the
LVOT-AO and the final depth of the bioprosthesis.
The only study that addressed the predictors for AR after
AVI was conducted by Detaint et al. (10), who related the
ccurrence of significant AR to prosthesis/annulus discongru-
nce in patients treated with the Edwards-Sapien valve. The
edtronic CoreValve bioprosthesis is a long device (53 mm
or the 26-mm inflow device, and 55 mm for the 29-mm
racteristics oforeValve Bi prosthesiscedu al Characteristic of
Medtronic CoreValve Bioprosthesis
AR <2 (n  30) AR >2 (n  20) p Value
80.50 7.99 80.55 7.83 0.98
170.96 8.78 168.45 8.10 0.31
78.60 17.04 73.75 11.36 0.27
1.94 0.25 1.87 0.17 0.22
26.93 5.31 26.00 3.52 0.49
50.23 14.81 50.60 20.70 0.94
0.64 0.18 0.64 0.16 0.92
0.33 0.10 0.34 0.09 0.72
23.50 1.48 22.90 1.25 0.14
17 (56.7%) 10 (50.0%) 0.64
13 (43.3%) 10 (50.0%)
16 (53.3%) 12 (60.0%) 0.62
5.09 1.63 6.11 2.02 0.055
5.38 1.70 5.97 2.00 0.27
13.73 2.60 15.05 3.23 0.12
0.80 0.66 1.00 0.72 0.32
12 (40.0%) 7 (35.0%) 0.73
47.30 13.38 46.45 13.09 0.82
52.66 8.89 51.90 12.56 0.80
15.70 4.71 25.60 8.19 0.01
29.73 3.40 29.75 3.41 0.98
30.06 4.95 30.00 3.75 0.95
9.75 2.49 11.43 4.94 0.17
11.00 2.69 11.81 4.93 0.47
22.43 1.73 22.20 1.43 0.62
13 (43.3%) 7 (35.0%) 0.57
17 (56.7%) 13 (65.0%) 0.56
1.88 0.15 1.90 0.15 0.65
0.99 0.14 1.01 0.15 0.68Chanic Cd Pro
f theVA indexed aortic valve area; IVS interventricular septum; LCC left coronary cusp; LVEDD
utflow tract; NCC  noncoronary cusp; RCC  right coronary cusp.
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November 9, 2010:1623–9 Predictors of AR After TAVInflow device) and allows for a wide range of implant depths.
oreover, the hemodynamic performance of the prosthesis
ithin the aortic annulus may depend on a number of factors
elating to the ascending aorta, the LVOT, annulus shape,
egree of contact with the aortic annulus, degree of calcifica-
ion and thickness of the aortic valve leaflets, and the ability of
he nitinol stent to provide a radial force. It is quite obvious
Figure 3 Correlation Between Angiographic and
Echocardiographic Grading of Post-Procedural AR
Using Spearman rho correlation, the angiographic grading of aortic regurgitation
(AR) correlated well with the echocardiographic grading (r  0.8, p  0.001).
“Jitter” has been used to show multiple plots.
Predictors of Significant Aortic Regurgitation inAfter Implantatio of the Medtronic CoreValve BTable 2 Predictors of Significant Aortic RegAfter Implantation of the Medtronic
Variable Estimated Coeffi
Univariate regression model
LVOT-AO 0.21
Depth to NCC, mm 1.76
Depth to NCC squared 0.09
Depth to LCC, mm 1.33
Depth to LCC squared 0.06
NCC thickness, mm 0.32
Asymmetric calcification 0.21
Ejection fraction, % 0.005
Degree of leaflet calcification 0.23
IVS diameter, mm 0.16
Ascending aorta diameter, mm 0.004
Sinus of Valsalva diameter, mm 0.002
LVEDD diameter, mm 0.01
Baseline AR 0.43
Oval annulus 0.39
Valve size 0.35
Multivariate regression model for
the independent predictors
LVOT-AO 0.21
Depth to NCC, mm 1.82
Depth to NCC squared 0.09CI  confidence interval; OR odds ratio; other abbreviations as in Table 1.hat these parameters in combination determine the hemody-
amic results of implantation.
In our series, we found that the LVOT-AO is the
trongest independent determinant contributing to the oc-
urrence of significant AR after implantation of the Core-
alve bioprosthesis. A greater angle may affect the radial
orce of the prosthesis and its ability to completely seal the
aravalvular space. Moreover, nitinol stent deformation,
elped by the stiffness of the aorta and the calcific nature of
he aortic root and valve, may be another factor in this
ontext. The net result will be inability of the prosthesis to
eal the gap between it and the aortic annulus, causing
aravalvular AR.
The depth of the device is also an important factor. Very
eep implantation results in severe AR, because the covered
kirt would be situated below the native annulus, allowing
lood to regurgitate through the holes of the uncovered
ortion of the stent frame (11). Likewise, high implantation
esults in malapposition of the prosthesis, allowing blood to
ow in the space between prosthesis and annulus. Jilaihawi
t al. (11) recently underscored the importance of final
evice depth in avoiding patient-prosthesis mismatch. They
efined an “optimal” depth of 5 mm to 10 mm below the
ative NCC as measured on fluoroscopy. We have found
hat the optimal depth of the device that correlates with a
inimal chance of AR is 10 mm; deeper or shallower
mplantations result in more degrees of AR. Therefore, we
elieve that implantation of the device at that depth can result
n optimal hemodynamics, taking into consideration the
atientss hesisation in 50 Patients
Valve Bioprosthesis
i
Standard
Error OR (95% CI) p Value
0.06 1.24 (1.10–1.39) 0.01
0.71 0.02 (0.04–0.70) 0.01
0.03 1.10 (1.02–1.18) 0.01
0.63 0.26 (0.08–0.90) 0.035
0.03 1.07 (1.01–1.13) 0.03
0.17 1.38 (0.98–1.95) 0.07
0.37 0.81 (0.40–1.67) 0.57
0.02 0.99 (0.95–1.04) 0.82
0.49 1.26 (0.49–3.28) 0.63
0.11 1.18 (0.95–1.46) 0.13
0.06 1.00 (0.88–1.13) 0.96
0.09 1.00 (0.85–1.19) 0.99
0.03 0.99 (0.94–1.05) 0.80
0.43 1.54 (0.66–3.60) 0.32
0.62 1.48 (0.44–5.04) 0.53
0.59 0.70 (0.22–2.27) 0.56
0.06 1.24 (1.09–1.41) 0.01
0.85 0.16 (0.03–0.85) 0.03
0.04 1.10 (1.01–1.19) 0.0250 Pioprourgit
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Predictors of AR After TAVI November 9, 2010:1623–9LVOT-AO. Moreover, in this sense, we found that a
ifference of 3.4 mm in the depth above or below the NCC
s equivalent to an angle difference of 5° (data not shown).
linical implications. To prevent AR after TAVI, first,
e should pay more attention to the LVOT-AO, which
Figure 4 ROC Curve for Predictive Model
for Occurrence of Post-Procedural AR
The receiver-operating characteristic (ROC) curve of the predictive model for the
occurrence of significant post-procedural aortic regurgitation (AR) is shown.
Area under the curve: 0.89; 95% confidence interval (obtained using the boot-
strap method): 0.78 to 0.98. To decide on a good value for k, an ROC curve
was plotted, and we looked for values of k where the curve is close to the
point (0, 1). This method suggested using k  4.0459, so that the test is
positive if: 0.21314  LVOT-AO  1.8242  depth  0.091  (depth to
NCC)2  4.0459, with a sensitivity of 90% and a specificity of 86.7%.
LVOT-AO  angle of left ventricular outflow tract to ascending aorta; NCC 
noncoronary cusp.
Figure 5 Scatter Plot of Calculated Score and Degree of AR in
Of note, all patients with aortic regurgitation (AR) grade III (blue spheres) and all b
Conversely, 6 patients with AR grade I (green spheres) have a score  50. Orangould be simply measured during the pre-procedural prepa-
atory phase. Second, we should try to deploy the prosthesis
s discussed in the preceding text. Using imaging modalities
ike TEE in addition to fluoroscopy may be warranted (12).
ased on the data presented and the predictive model we
eveloped, patients with angles 25° may be offered other
ptions. In patients with smaller angles, the final depth of
he implanted bioprosthesis should be properly checked.
So far, there is no study that has addressed the short- and
ong-term clinical impact of significant AR after TAVI. In
n experimental model, Azadani et al. (13) found that,
wing to the paravalvular leaks, TAVI imposes a signifi-
antly higher workload on the left ventricle than an equiv-
lently sized surgically implanted bioprosthesis. Future
tudies with long-term follow-up periods are needed to
tudy the clinical impact of this complication.
tudy limitations. The values for sensitivity and specificity of
he predictive model are quite promising. However, we need to
e aware that we have tailored the predictive model specifically
o this dataset, and that the sensitivity and specificity for the
ame test used on independent data may be different. Although
he multivariable model has been obtained using a standard
ethod and seems in accord with clinical expectations, further
tudies are required to confirm its form. However, it is often
he case that models with entirely different sets of prognostic
ariables can provide almost as good a fit. Another limitation is
hat the LVOT-AO was not determined reproducibly or
lindly, and the model requires a blinded analysis in another
ataset for confirmation. Finally, owing to different designs of
he available TAVI devices, the presented model is applied
nly to the Medtronic CoreValve bioprosthesis and not to
ther devices.
hole Cohort
atients with AR grade II (red spheres) have a score 50.
res indicate no AR.the W
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he occurrence of significant AR after TAVI remains a
afety concern. We found that occurrence of AR after TAVI
sing the Medtronic CoreValve bioprosthesis depends on
n interaction between anatomic and procedural variables. A
odel such as that presented, after validation in larger
eries, could be used to select the suitable patients for this
rocedure and guide the operators during implantation of
he device.
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